Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 20/20 | 0.73 |
| ▸ | LIFR | P42702 | 4/20 | 0.57 |
| ▸ | PPARD | Q03181 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | FABP1 | P07148 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.54 |
| ▸ | VDR | P11473 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4433875 | 0.94 | NR1H4 (0.71) | NR1H4LIFRVDR | |
| SCHEMBL4425445 | 0.93 | NR1H4 (0.73) | NR1H4LIFRPPARDMEN1FABP1 | |
| SCHEMBL4435997 | 0.93 | NR1H4 (0.71) | NR1H4LIFRMEN1FABP1THRB | |
| SCHEMBL4831057 | 0.90 | NR1H4 (0.80) | NR1H4LIFRPPARD | |
| SCHEMBL4435424 | 0.87 | NR1H4 (0.71) | NR1H4LIFRMEN1FABP1THRB | |
| SCHEMBL4598356 | 0.87 | NR1H4 (0.78) | NR1H4LIFRPPARDMEN1FABP1 | |
| SCHEMBL4433691 | 0.87 | NR1H4 (0.71) | NR1H4LIFRMEN1FABP1THRB | |
| SCHEMBL4427073 | 0.87 | NR1H4 (0.69) | NR1H4LIFRVDR | |
| SCHEMBL2129745 | 0.86 | NR1H4 (0.64) | NR1H4LIFR | |
| SCHEMBL28530824 | 0.85 | NR1H4 (1.00) | NR1H4LIFRPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194494-A1 | 4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia | MICROBIA, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| WO-2008039829-A2 | DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2008-04-03 | — | — | WO | disclosed |
| EP-1885694-A2 | 4-BIARYLYL-1-PHENYLAZETIDIN-2-ONES | Microbia, Inc. (US) | 2008-02-13 | — | — | EP | disclosed |
| EP-1879860-A2 | 1,4-DIPHENYL-3-HYDROXYALKYL-2-AZETIDINONE DERIVATIVES FOR TREATING HYPERCHOLESTROLEMIA | Microbia Inc. (US) | 2008-01-23 | — | — | EP | disclosed |
| US-7319109-B2 | Farnesoid X receptor agonists | SMITH KLINE BEECHAM CORPORATION (US) | 2008-01-15 | — | — | US | disclosed |
| US-7319109-B2 | Farnesoid X receptor agonists | SMITH KLINE BEECHAM CORPORATION (US) | 2008-01-15 | — | — | US | disclosed |
| US-7319109-B2 | Farnesoid X receptor agonists | SMITH KLINE BEECHAM CORPORATION (US) | 2008-01-15 | — | — | US | disclosed |
| WO-2006124713-A2 | 4-BIARYLYL-1-PHENYLAZETIDIN-2-ONES | MICROBIA, INC. (US) | 2006-11-23 | — | — | WO | disclosed |
| US-20060258725-A1 | Farnesoid x receptor agonists | SMITHKLINE BEECHAM CORPORATION | 2006-11-16 | — | — | US | disclosed |
| WO-2006122186-A2 | 1,4-DIPHENYL-3-HYDROXYALKYL-2-AZETIDINONE DERIVATIVES FOR TREATING HYPERCHOLESTROLEMIA | MICROBIA, INC. (US) | 2006-11-16 | — | — | WO | disclosed |
| EP-1562915-A1 | FARNESOID X RECEPTOR AGONISTS | SmithKline Beecham Corporation (US) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004048349-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194494-A1 | 4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia | CYP46A1, CYP7A1, UGT1A1 | NR1H4 24/4885LIFR 4437/4885PPARD 313/4885 |
| US-20060258725-A1 | Farnesoid x receptor agonists | NR1H4, GPBAR1, NR1H2 | NR1H4 1/4885LIFR 2155/4885PPARD 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.